KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Depreciation & Amortization (CF) (2016 - 2025)

BeOne Medicines (ONC) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $36.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 28.38% to $36.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $141.7 million, a 17.51% decrease, with the full-year FY2025 number at $141.7 million, down 17.51% from a year prior.
  • Depreciation & Amortization (CF) was $36.0 million for Q4 2025 at BeOne Medicines, down from $37.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $71.3 million in Q3 2024 to a low of $9.6 million in Q1 2021.
  • A 5-year average of $25.7 million and a median of $21.9 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 231.44% in 2024, then plummeted 47.7% in 2025.
  • BeOne Medicines' Depreciation & Amortization (CF) stood at $13.1 million in 2021, then surged by 37.31% to $18.0 million in 2022, then soared by 32.21% to $23.8 million in 2023, then soared by 110.95% to $50.2 million in 2024, then fell by 28.38% to $36.0 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Depreciation & Amortization (CF) are $36.0 million (Q4 2025), $37.3 million (Q3 2025), and $35.6 million (Q2 2025).